Floatz logo

LEUPROLIDE

Myeloproliferative Neoplasm

Masonic Cancer Center, University of Minnesotaprotein_peptidePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

80 Active assets in the Myeloproliferative Neoplasm cohort.

Asset / SponsorPhaseRating
Evomela
Center for International Blood and Marrow Transplant Research
Phase 2/3BBB
Fludarabine
Sawa Ito, MD
Phase 4BB
Anti-Thymoglobulin, Rabbit
Fred Hutchinson Cancer Center
Phase 2/3BB
Busulphan
Sawa Ito, MD
Phase 4BB
CYCLOSPORIN A
City of Hope Medical Center
Phase 3BB

View all 50 →

Same molecule, other indications

LEUPROLIDE is also rated in:

prostate carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
metastatic prostate carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
prostate neoplasmDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →